Displaying drugs 51 - 75 of 1616 in total
APL-030
APL-030 is a orally-active small molecule inhibitor of GCN2.
Investigational
Matched Name: … APL-030 …
Matched Description: … APL-030 is a orally-active small molecule inhibitor of GCN2. …
Matched Description: … APL-030 is a orally-active small molecule inhibitor of GCN2. …
EHT 0202
EHT 0202 is developed to treat neurodegenerative disorders by ExonHit Therapeutics.
Investigational
Matched Name: … EHT 0202 …
Matched Description: … EHT 0202 is developed to treat neurodegenerative disorders by ExonHit Therapeutics. …
Matched Description: … EHT 0202 is developed to treat neurodegenerative disorders by ExonHit Therapeutics. …
AZD-0328
AZD0328 has been used in trials studying the treatment and basic science of Schizophrenia and Alzheimer's Disease.
Investigational
Matched Name: … AZD-0328 …
GDC-0152
GDC-0152 has been used in trials studying the treatment of Solid Cancers.
Investigational
Matched Name: … GDC-0152 …
Matched Description: … GDC-0152 has been used in trials studying the treatment of Solid Cancers. …
Matched Description: … GDC-0152 has been used in trials studying the treatment of Solid Cancers. …
PLG-0206
PLG-0206 is a peptide antibiotic under investigation for the treatment of periprosthetic joint infections.
Investigational
Matched Name: … PLG-0206 …
Matched Description: … PLG-0206 is a peptide antibiotic under investigation for the treatment of periprosthetic joint infections …
Matched Description: … PLG-0206 is a peptide antibiotic under investigation for the treatment of periprosthetic joint infections …
OSSM-007
OSSM-007 consists of interferon-gamma primed allogeneic mesenchymal stem cells.
Investigational
Matched Name: … OSSM-007 …
Matched Description: … OSSM-007 consists of interferon-gamma primed allogeneic mesenchymal stem cells. …
Matched Description: … OSSM-007 consists of interferon-gamma primed allogeneic mesenchymal stem cells. …
GLPG-0259
GLPG-0259 is under investigation in clinical trial NCT01024517 (GLPG0259 Solid Formulation Bioavailability and Food Effect).
Investigational
Matched Name: … GLPG-0259 …
Matched Description: … GLPG-0259 is under investigation in clinical trial NCT01024517 (GLPG0259 Solid Formulation Bioavailability …
Matched Description: … GLPG-0259 is under investigation in clinical trial NCT01024517 (GLPG0259 Solid Formulation Bioavailability …
ALMB-0166
ALMB-0166 is a umanized connexin 43 (Cx43) monoclonal antibody being investigated for the treatment of acute spinal cord injury. It was granted FDA orphan designation in November 2018.
Investigational
Matched Name: … ALMB-0166 …
Matched Description: … ALMB-0166 is a umanized connexin 43 (Cx43) monoclonal antibody being investigated for the treatment of …
Matched Description: … ALMB-0166 is a umanized connexin 43 (Cx43) monoclonal antibody being investigated for the treatment of …
DAR-0100A
DAR-0100A is under investigation in clinical trial NCT01466205 (Clinical Testing of a D1 Agonist for Cognitive Enhancement in Schizotypal Personality Disorder).
Investigational
Matched Name: … DAR-0100A …
Matched Description: … DAR-0100A is under investigation in clinical trial NCT01466205 (Clinical Testing of a D1 Agonist for …
Matched Description: … DAR-0100A is under investigation in clinical trial NCT01466205 (Clinical Testing of a D1 Agonist for …
PF-03882845
PF-03882845 has been used in trials studying the basic science of Diabetes Mellitus, Type 2 and Type 2 Diabetic Nephropathy.
Investigational
Matched Name: … PF-03882845 …
Matched Description: … PF-03882845 has been used in trials studying the basic science of Diabetes Mellitus, Type 2 and Type …
Matched Description: … PF-03882845 has been used in trials studying the basic science of Diabetes Mellitus, Type 2 and Type …
PF-04958242
PF-04958242 has been used in trials studying the basic science and treatment of Schizophrenia and Hearing Loss, Sensorineural.
Investigational
Matched Name: … PF-04958242 …
Matched Description: … PF-04958242 has been used in trials studying the basic science and treatment of Schizophrenia and Hearing …
Matched Description: … PF-04958242 has been used in trials studying the basic science and treatment of Schizophrenia and Hearing …
PF-00610355
PF-00610355 has been used in trials studying the treatment of Lung Disease, Moxifloxacin, Pulmonary Disease, Asthma, Bronchial, and Bronchial Diseases, among others.
Investigational
Matched Name: … PF-00610355 …
Matched Description: … PF-00610355 has been used in trials studying the treatment of Lung Disease, Moxifloxacin, Pulmonary Disease …
Matched Description: … PF-00610355 has been used in trials studying the treatment of Lung Disease, Moxifloxacin, Pulmonary Disease …
PF-04447943
PF-04447943 has been investigated for the treatment of Alzheimer's Disease.
Investigational
Matched Name: … PF-04447943 …
Matched Description: … PF-04447943 has been investigated for the treatment of Alzheimer's Disease. …
Matched Description: … PF-04447943 has been investigated for the treatment of Alzheimer's Disease. …
PF-04691502
PF-04691502 has been used in trials studying the treatment of Cancer, Breast Neoplasms, Early Breast Cancer (Phase 2), and Advanced Breast Cancer (Phase 1b).
Investigational
Matched Name: … PF-04691502 …
Matched Description: … PF-04691502 has been used in trials studying the treatment of Cancer, Breast Neoplasms, Early Breast …
Matched Description: … PF-04691502 has been used in trials studying the treatment of Cancer, Breast Neoplasms, Early Breast …
PF-03635659
Pf03635659 has been used in trials studying the treatment of Chronic Obstructive Pulmonary Disease.
Investigational
Matched Name: … PF-03635659 …
PF-04937319
PF-04937319 is under investigation in clinical trial NCT01513928 (A Study To Compare The Pharmacokinetics Of Different Formulations Of PF-04937319 In Healthy Subjects).
Investigational
Matched Name: … PF-04937319 …
Matched Description: … Of Different Formulations Of PF-04937319 In Healthy Subjects). ... PF-04937319 is under investigation in clinical trial NCT01513928 (A Study To Compare The Pharmacokinetics …
Matched Description: … Of Different Formulations Of PF-04937319 In Healthy Subjects). ... PF-04937319 is under investigation in clinical trial NCT01513928 (A Study To Compare The Pharmacokinetics …
PF-04856884
PF-04856884 or CVX-060 is a selective angiopoietin (Ang)-2 inhibitor. It is under investigation in clinical trial NCT01441414 (PF-04856884 (CVX-060) in Combination With Axitinib in Patients With Previously Treated Metastatic Renal Cell Carcinoma).
Investigational
Matched Name: … PF-04856884 …
Matched Description: … PF-04856884 or CVX-060 is a selective angiopoietin (Ang)-2 inhibitor. ... [A257291] It is under investigation in clinical trial NCT01441414 (PF-04856884 (CVX-060) in Combination …
Matched Description: … PF-04856884 or CVX-060 is a selective angiopoietin (Ang)-2 inhibitor. ... [A257291] It is under investigation in clinical trial NCT01441414 (PF-04856884 (CVX-060) in Combination …
WVE-003
WVE-003 is an allele-selective antisense oligonucleotide that works to selectively reduce the toxic mutant huntingtin (mHTT) protein.
Investigational
Matched Synonyms: … WVE 003 …
Matched Name: … WVE-003 …
Matched Description: … WVE-003 is an allele-selective antisense oligonucleotide that works to selectively reduce the toxic mutant …
Matched Name: … WVE-003 …
Matched Description: … WVE-003 is an allele-selective antisense oligonucleotide that works to selectively reduce the toxic mutant …
AL-034
AL-034 (TQ-A3334) is an oral toll-like receptor 7 agonist developed for the treatment of chronic hepatitis B (CHB) viral infection.
Investigational
Matched Name: … AL-034 …
Matched Description: … AL-034 (TQ-A3334) is an oral toll-like receptor 7 agonist developed for the treatment of chronic hepatitis …
Matched Description: … AL-034 (TQ-A3334) is an oral toll-like receptor 7 agonist developed for the treatment of chronic hepatitis …
LTI-03
LTI-03 is a caveolin-1 Scaffolding Domain 7-Mer
Investigational
Matched Name: … LTI-03 …
Matched Description: … LTI-03 is a caveolin-1 Scaffolding Domain 7-Mer …
Matched Description: … LTI-03 is a caveolin-1 Scaffolding Domain 7-Mer …
HH-009
HH-009 is a recombinant human IgG4 monoclonal antibody against FGF19 being studied for the treatment of hepatocellular carcinoma.
Investigational
Matched Name: … HH-009 …
Matched Description: … HH-009 is a recombinant human IgG4 monoclonal antibody against FGF19 being studied for the treatment …
Matched Description: … HH-009 is a recombinant human IgG4 monoclonal antibody against FGF19 being studied for the treatment …
Displaying drugs 51 - 75 of 1616 in total